Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients

Conclusions Single agent ZA was associated with encouraging progression-free survival in four consecutive patients with metastatic osteosarcoma. Prospective trials of single agent ZA are warranted as protracted maintenance therapy in surgically incurable osteosarcoma relapsed or refractory to first line combination chemotherapy with radiographically measurable metastases.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research